Invetech Videos

  1. Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy 4/15/2021

    One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remain open – introducing opportunities for failures. Invetech’s approach enables manufacturers to close and integrate both core and peripheral processes.

  2. True Innovations In Driving Down Cell Therapy Manufacturing 2/26/2021

    In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka talk through the innovations in the manufacturing processes for both autologous and allogeneic therapies.

  3. The Why Behind The Expense Of Cell Therapy Manufacturing 2/26/2021

    In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka address the reasons why cell manufacturing has been expensive to date — from viral vector production to the quality testing of a single-lot product, and more.

  4. The Current Challenges Facing Cell Therapy Manufacturing 2/26/2021

    In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka explain the many current challenges associated with cell therapy manufacturing.

  5. How Automation Drives Down Cell Therapy Manufacturing Costs 2/26/2021

    In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka discussed how automation drives down manufacturing costs and the long road ahead to achieve continuous improvement.

  6. Cell Therapy Manufacturing And Economies Of Scale 2/26/2021

    In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka discussed why autologous and allogeneic therapies are, in fact, scalable as well as the hurdles and wins associated with achieving scalability.

  7. Can Innovation Drive Down Cell Therapy Manufacturing Costs? 1/27/2021

    The high cost of producing new cell and gene therapies is one of the largest issues facing the industry. After launching Kymriah and Yescarta, Novartis’ price tags were $475,000 and $375,000, respectively. Advancements in manufacturing are driving costs down, but not at the required pace.

  8. 3rd Generation Filling System Video 1/25/2021

    3rd Generation Filling System is an automated bag filling platform for GMP manufacturing.

  9. Cell And Gene Therapy Formulation And Fill Platform 1/25/2021

    Solving commercial manufacturing challenges in cell and gene therapy.

  10. Invetech 3rd Generation Filling System 1/21/2021

    Invetech's 3rd generation filling system is an automated bag filling platform for GMP manufacturing. Watch this video to see a glimpse of the core capabilities of this system.